The incidence of female urogenital tract infection around the world is more than 300 million cases per annum. Bacterial Vaginosis (BV) represents the most common vaginal syndrome afflicting premenopausal and pregnant women, with an incidence rate ranging from 10% to 50%. BV is complex, polymicrobial disorder characterized by an overgrowth of strict or facultative anaerobic bacteria (Gardnerella vaginalis, Prevotella, Mobiluncus, Mycoplasma horminis) and a reduction of lactobacilli particularly those producing hydrogen perioxide. BV is frequently underestimated since the symptoms are often insignificant, however, the clinical consequences could be important.  Cure rate of Bacterial Vaginosis with oral or local administration of metronidazole or intravaginal Clindamycin, ranges from 48-85%, however, 40% of women relapse within 3 months after initiation of antibiotic therapy and up to 50% of women after 6 months. The high recurrence rates with repeated exposure to antibiotics, results in the emergence of drug resistant strains. Since reduction of lactobacilli and increase in pH are the main pathogenesis of BV, probiotics have been suggested as a tool to treat and prevent BV. So this study has been designed to evaluate the efficacy and safety of probiotic Supplementation (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 Strains) in Indian Adult Pregnant Women with Bacterial Vaginosis.

 In order to fulfil the objectives of the study 400 women in 28^th week of gestation will be screened for BV based Nugent’s criteria. Then if they are meeting the mentioned inclusion and exclusion criteria then they will be recruited into the study after the written consent. Of the 400 pregnant women, 100 women who are positive for BV will be randomized to50 in each group to receive either probiotics (Lactobacillus rhamnosus GR-1, L.reuteri RC-14) capsule or placebo capsule will be supplemented during third trimester till delivery. All women with BV will be treated with local antibiotic (Clindamycin) for a period of 5-7 days. The recruited subjects will be followed for 6 months that is 3 months (last trimester of pregnancy) during pregnancy and 3 months after delivery.  Bacterial Vaginosis and Vaginal flora will be assessed at baseline and at 34, 38 weeks of gestation and 3 months after delivery to ensure persistence of supplemented strains and non-recurrence of BV. After delivery neonate stool and breast milk samples will be collected from 5th to 10th day of birth, and again at 3rd month. The outcome of the study will be cure rate of BV in women with and without probiotics and rate of recurrence of BV with probiotics.